These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39152750)

  • 1. Efficacy of intravenous immunoglobulins in severe scleromyxedema dysphagia assessed by oesophageal scintigraphy.
    Di Battista M; Grosso M; Marciano A; Scarpuzza M; Della Rossa A; Mosca M
    Clin Exp Rheumatol; 2024 Aug; 42(8):1706. PubMed ID: 39152750
    [No Abstract]   [Full Text] [Related]  

  • 2. [Good response of scleromyxedema and dermato-neuro syndrome to treatment with intravenous immunoglobulins].
    Bielsa I; Benvenutti F; Guinovart RM; Ferrándiz C
    Actas Dermosifiliogr; 2012 May; 103(4):317-20. PubMed ID: 21917233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myopathy and scleromyxedema.
    Soulages A; Tang HM; Pham-Ledard A; Négrier-Leibreich ML; Cosnard A; Duval F; Solé G; Carla L; Le Masson G; Mathis S
    J Neurol; 2019 Aug; 266(8):2051-2059. PubMed ID: 31115676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scleroderma-like acute renal crisis in a patient with scleromyxedema.
    Gwinner W; Erdbruegger U; Mengel M; Hafer C; Kittner J; Witte T; Voelker B; Haller H
    Nephrol Dial Transplant; 2007 Jul; 22(7):2063-7. PubMed ID: 17389621
    [No Abstract]   [Full Text] [Related]  

  • 5. [Scleromyxedema with neurological symptoms: successful treatment with immunoglobulins].
    Manríquez J; Berroeta-Mauriziano D; Andino-Navarrete R; Vera-Kellet C
    Med Clin (Barc); 2015 Jan; 144(1):47-8. PubMed ID: 24656121
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema.
    Brunet-Possenti F; Hermine O; Marinho E; Crickx B; Descamps V
    J Am Acad Dermatol; 2013 Aug; 69(2):319-20. PubMed ID: 23866873
    [No Abstract]   [Full Text] [Related]  

  • 7. Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy.
    Manousaridis I; Loeser C; Goerdt S; Hassel JC
    Acta Dermatovenerol Alp Pannonica Adriat; 2010 Dec; 19(4):15-9. PubMed ID: 21390475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin.
    Rey JB; Luria RB
    J Am Acad Dermatol; 2009 Jun; 60(6):1037-41. PubMed ID: 19249127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recovery of barium swallow radiographic abnormalities in a patient with dermatomyositis and severe dysphagia after high-dose intravenous immunoglobulins.
    Iannone F; Giannini M; Lapadula G
    J Clin Rheumatol; 2015 Jun; 21(4):227. PubMed ID: 26010190
    [No Abstract]   [Full Text] [Related]  

  • 10. Fever, Joint Pain, Seizures, and Rash in a 53-Year-Old Woman.
    Weiner J; Marano A; Cardones A; Criscione-Schreiber L
    Arthritis Care Res (Hoboken); 2017 Sep; 69(9):1437-1443. PubMed ID: 28376294
    [No Abstract]   [Full Text] [Related]  

  • 11. Value of radionuclide oesophageal transit in studies of functional dysphagia.
    Llamas-Elvira JM; Martinez-Parades M; Sopena-Monforte R; Garrigues V; Cano-Terol C; Velasco-Lajo T
    Br J Radiol; 1986 Nov; 59(707):1073-8. PubMed ID: 3790892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin for dysphagia of inclusion body myositis.
    Cherin P; Pelletier S; Teixeira A; Laforet P; Simon A; Herson S; Eymard B
    Neurology; 2002 Jan; 58(2):326. PubMed ID: 11805271
    [No Abstract]   [Full Text] [Related]  

  • 13. Diffuse oesophageal involvement in anti-NXP2 myositis and response to combined immunosuppressive therapy.
    Fanouriakis A; Lazarini A; Sofianos I; Papadopoulos C; Bagiazidou E; Balanika A; Elezoglou A
    Rheumatology (Oxford); 2021 Nov; 60(11):e378-e380. PubMed ID: 33956080
    [No Abstract]   [Full Text] [Related]  

  • 14. Scleromyxedema Without Monoclonal Gammopathy Treated with Intravenous Immunoglobulins.
    Letzelter M; Grimaux X
    Acta Dermatovenerol Croat; 2021 Apr; 291(1):51-53. PubMed ID: 34477065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oesophageal scintigraphy for the investigation of dysphagia: in ans out of favour - underused when available.
    Stacey B; Patel P
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1216-20. PubMed ID: 12418460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of intravenous immunoglobulin in Arndt-Gottron scleromyxedema].
    Lopez L; Wierzbicka-Hainaut E; Villers A; Guillet G
    Ann Dermatol Venereol; 2009 Apr; 136(4):330-6. PubMed ID: 19361699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncommon Presentation of Scleromyxoedema with a Distribution Pattern Mimicking a Photodermatosis.
    Kirchberger MC; Sticherling M; Erdmann M
    Acta Derm Venereol; 2017 Aug; 97(8):979-980. PubMed ID: 28421236
    [No Abstract]   [Full Text] [Related]  

  • 18. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG).
    Blum M; Wigley FM; Hummers LK
    Medicine (Baltimore); 2008 Jan; 87(1):10-20. PubMed ID: 18204366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Efficacy of Treatment with Intravenous Immunoglobulin in Scleromyxedema.
    Baglama Š; Trčko K
    Acta Dermatovenerol Croat; 2020 Jul; 28(1):24-28. PubMed ID: 32650847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins.
    Gholam P; Hartmann M; Enk A
    Br J Dermatol; 2007 Nov; 157(5):1058-60. PubMed ID: 17854360
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.